Introduction

GVAX
s vaccines are composed of whole tumor cells genetically modified to secrete granulocyte-macrophage colony-stimulating factor (GM-CSF). Animal studies have consistently demonstrated the safety and antitumor activity of GVAX s vaccines. [1] [2] [3] Preclinical data also suggest that a threshold of vaccine-associated GM-CSF secretion is necessary to induce optimal antitumor immunity. 4 Clinical trials have been performed in a variety of tumor types, including melanoma, [5] [6] [7] prostate, 8 renal cell, 9 pancreatic, 10 and lung cancer. 11, 12 Vaccine treatment has been consistently well tolerated and clinical activity has been demonstrated.
Initial exploration of GVAX vaccines in advancedstage non-small-cell lung cancer (NSCLC) employed a patient-specific vaccine platform generated by genetic modification of autologous tumor cells with a nonreplicating adenoviral vector containing the gene for GM-CSF. Tumor-specific immune responses including inflammatory infiltrates in metastatic tumor masses and delayed-type hypersensitivity (DTH) reactions to injections of autologous tumor cells were demonstrated; however, no objective tumor responses were observed. Two patients who underwent complete surgical resection of their metastatic lesions before vaccine treatment remained disease free for more than 3 years. 12 A subsequent multicenter clinical study in NSCLC demonstrated convincing evidence of vaccine activity with three of 33 treated patients with metastatic disease demonstrating complete tumor responses. Furthermore, survival was positively associated with vaccine production of GM-CSF above a minimum threshold. 11 However, vaccineassociated GM-CSF secretion was variable and 21% of vaccine lots fell below 40 ng GM-CSF/10 6 cells/24 h, the threshold associated with longer survival.
Based on preclinical data demonstrating similar activity of fully autologous vaccines and vaccines composed of unmodified tumor cells mixed with a GM-CSF-secreting bystander cell line, 13 we modified the current vaccine by combining freshly harvested autologous lung tumor cells (as a source of tumor antigen) with a bystander cell line, K562 (human erythroleukemia cell line), genetically modified to secrete GM-CSF (CG9962). The combination is referred to as 'bystander GVAX s '. Manufacturing of bystander GVAX s does not require genetic modification of individual autologous tumor cell preparations, and provides substantially higher and more consistent GM-CSF secretion. We now report the results of a phase I/II clinical trial evaluating this bystander GVAX vaccine in advanced-stage NSCLC.
Patients and methods
Patient population
Patients were enrolled at four clinical sites after institutional review board approval and written informed consent was obtained. For tumor procurement, patients were required to have an accessible tumor source for vaccine production and suspicious diagnosis of stage IIIA, IIIB, or IV NSCLC. Stage IIIA patients must have failed or refused standard therapy. No prior chemotherapy or radiotherapy within 4 weeks of tumor harvest, and more than 2 weeks from therapeutic thoracentesis (if procurement of malignant pleural effusion was planned) was required. Patients were required to have an ECOG performance status of 0-1, to be at least 18 years of age, and have no history of active autoimmune diseases or other medical conditions requiring immunosuppressant medications.
Eligibility criteria for proceeding to vaccine treatment included histologic confirmation of NSCLC from the harvested tumor sample, successful vaccine preparation, acceptable organ function, oxygen saturation of at least 90% on not more than 2 l of supplemental oxygen, ECOG performance status of 0-2, and no additional intervening cancer therapy other than local palliative radiation. Patients were excluded if they had active or untreated brain metastases, were HIV seropositive, had a history of other significant malignancies over the past 5 years, or evidence of spinal cord compression or other uncontrolled medical problems.
Vaccine preparation and administration Autologous tumor processing. Eligible patients underwent a surgical procedure (or thoracentesis) to obtain tumor for vaccine preparation. A sample was submitted for routine pathological evaluation to confirm the diagnosis of NSCLC. The remaining tumor/pleural effusion was shipped at 41C to a central processing facility (US Oncology, Dallas, TX). Solid tumors were processed to a single-cell suspension by mechanical and enzymatic digestion for 45-60 min in media containing collagenase (Invitrogen Life Technologies, Grand Island, NY) and fetal bovine serum (JRH Biosciences, Lenexa, KS) using a Stomacher laboratory blender (Brinkmann, Westbury, NY). Pleural effusions were subjected to Ficol (Amersham Biosciences AB, Uppsala, Sweden) density gradient separation. The single-cell suspension was irradiated at 10 000 rad for cell growth arrest, formulated in cryoprotectant medium, and filled in vials containing 5, K562 bystander GVAX (CG9962). K562 is an erythroleukemia cell line. K562 bystander GVAX s (CG9962) was generated by transfection of the parental cell line with a GM-CSF-containing bacterial plasmid as previously described. 13 A high-expressing clone was selected, adapted to serum-free growth, expanded, and characterized to be used as a bystander cell source of GM-CSF. 13 Clinical lots of CG9962 were required to secrete 4500 ng GM-CSF/10 6 cells/24 h. CG9962 clinical grade product was provided by Cell Genesys Inc. These cells were prepared under cGMP conditions, irradiated, cryopreserved, and stored in vapor-phase liquid nitrogen. Each CG9962 product vial contained 2 Â 10 7 cells/ml (1.25 ml/vial).
Final vaccine preparation. Processed autologous lung tumor and CG9962 cells were shipped frozen to the clinical sites and stored in vapor-phase liquid nitrogen until use. The final vaccine was generated by combining autologous, irradiated, lung tumor cells with CG9962 cells at a ratio of 2:1. At the time of administration, the two components were rapidly thawed in a 371C water bath and mixed together in a syringe. Irradiated, autologous tumor DTH test cells were rapidly thawed and administered as a single 0.5 ml intradermal injection.
Vaccine administration. Vaccinations were administered intradermally every 2 weeks for a total of 3-12 vaccinations. No pre-medications were given. The vaccine dose was individualized for each patient based on the total autologous tumor cell yield and ranged from 5 to 80 Â 10 6 tumor cells/vaccine. Patients were treated at the highest dose level achievable based on tumor cell yield. All dose cohorts were enrolled and treated concurrently. Table 3 outlines the tumor cell, CG9962, and GM-CSF dose delivered at each dose level. The final mixed vaccine was administered intradermally on the upper or lower extremities on a rotating basis at 0.5 cm 3 per injection with up to eight injections per vaccination. Autologous, irradiated, tumor DTH test cells were administered at a distant site from vaccine administration on the day of the first and third vaccination and a biopsy of the injection site was performed 48-72 h following administration.
GM-CSF pharmacokinetics
A subset of patients assigned to dose levels 4 and 5 returned to the clinic on days 1, 2, 3, and 4 following the first and third vaccination for serum GM-CSF measurements and complete blood counts as a measure of vaccine-associated GM-CSF secretion and biologic activity. Levels of GM-CSF in human serum were measured by a quantitative sandwich ELISA using the Quantikine s HS human GM-CSF Immunoassay kit (R&D Systems, Minneapolis, MN). The presence of antibodies against human GM-CSF was evaluated by measuring the recovery of a known quantity of recombinant human GM-CSF spiked into the patient serum. We have demonstrated (data not shown) that the addition of neutralizing and non-neutralizing GM-CSF antibodies (BD Biosciences Pharmingen, San Diego, CA) to human serum can effectively decrease the detectable level of GM-CSF by ELISA.
Immune response evaluations
Immune responses were evaluated by measurement of vaccine and tumor DTH skin reactions using the diameter of induration. The histology of DTH injection site punch biopsies was analyzed using standard techniques. Serum antibodies against autologous lung tumor (when available), CG9962, allogeneic lung tumor cell lines (520, 596, 441, 2347), the prostate tumor cell line, PC3, and the pancreatic cell line, 10.05, before and after vaccination were assayed by immunoblotting (Cell Genesys) using standard techniques. Briefly, lysates prepared from tumor cells were separated by denaturing gel electrophoresis (Invitrogen, Carlsbad, CA), transferred to nitrocellulose membrane, and incubated with serial dilutions of patient serum. Reactivity to lysate proteins was detected by incubation with a horseradish peroxidase-conjugated goat anti-human IgGAM secondary antibody (Zymed, S San Francisco, CA) and an ECL chemiluminescent detection method (Amersham, Piscataway, NJ).
Statistical analyses
The primary end points of this study were safety and vaccine manufacturing feasibility. Secondary end points included serum GM-CSF pharmacokinetics, immune response, tumor response, disease progression, and survival. Adverse events were recorded using NCI common toxicity criteria. Manufacturing feasibility assessment included analysis of autologous tumor cell yields, viability, sterility, and the feasibility of final vaccine preparation. Tumor staging was performed at baseline and week 12 and response was evaluated using standard Southwestern Oncology Group criteria.
14 Progression-free and overall survival were calculated from the date of tumor harvest for both the intent-totreat (all harvested) and vaccine-treated populations using the Kaplan-Meier method. Exploratory association analyses between manufacturing, clinical, and immunologic variables were performed using Spearman's rank, Wilcoxon's rank, Fisher's exact test, and Cox proportional hazards regression, depending on the nature of the variables analyzed (continuous or categorical). All tests of significance were two-sided. No statistical corrections were made for the multiplicity of tests performed.
Results
Patient population
A total of 86 patients were enrolled and underwent tumor harvest for vaccine preparation and 49 proceeded to vaccine treatment. A total of 39 patients were not treated owing to disease progression or death (15) , vaccine manufacturing failure (9) , lack of confirmation of NSCLC (5), and withdrawal of consent (2) . Baseline characteristics of both harvested and treated patients are shown in Table 1 . All except one patient had an ECOG performance status of 0 or 1 both at the time of tumor harvest and at initiation of vaccine treatment. A total of 85% of harvested and treated patients had stage IV disease and more than 60% had received two or more prior chemotherapy regimens. The majority of patients had adenocarcinoma and two patients with bronchioloalveolar carcinoma were treated. Two patients underwent repeat tumor harvests, leading to a total of 88 harvest procedures. The lung was the most common source of tumor harvest, followed by metastatic lymph nodes and pleural effusions (Table 2) .
Vaccine manufacturing and treatment
Three clinical lots of CG9962 were used in the trial, secreting an average of 2624 ng GM-CSF/10 6 cells/24 h (range 2331-2775) with a mean viability of 73% (range 72-75). Processed autologous tumor cells were mixed 2:1 with CG9962 cells and administered by intradermal injection at 2-week intervals at dose levels ranging from 5 to 80Â 10 6 tumor cells/vaccination (Table 3 ). The median autologous tumor cell dose per vaccine was 40 Â 10 6 among all harvested patients and 20 Â 10 6 among Bystander GVAX vaccine in advanced-stage NSCLC J Nemunaitis et al treated patients. The GM-CSF dose delivered with each vaccine ranged from 6.5 to 104 mg/dose/24 h across the five dose levels evaluated. The median tumor cell viability post-freeze was 80% (range 30-95%). Three of 86 (3.5%) vaccine products failed sterility testing. In 76 of 86 (88%) patients, a minimum of three vaccine doses were successfully manufactured and released for clinical use. The median time from tumor procurement to vaccine release for the 49 treated patients was 35 days, and from tumor procurement to first vaccination, 56 days. The median total number of vaccine doses manufactured was eight and the number administered was six (range 1-12).
Safety
Vaccine treatment was generally well tolerated. The most common vaccine-related adverse events were injection site reactions (87%), fatigue (16%), dyspnea (12%), nausea (8%), and fever (8%). All injection site reactions were grade 1 or 2 in severity and consisted of erythema or swelling (89%), pruritus (57%), and pain or soreness at the injection site (36%). Five patients, treated at dose levels 2-5, reported a total of nine grade 3 or 4 possibly related adverse events, including dyspnea and/or respiratory failure in four and pulmonary embolus/tachycardia, back pain, and chest pain in one patient each. The frequency of related adverse events was similar across all dose levels. No clear evidence of vaccine-associated autoimmunity, specifically no hematologic toxicity due to the potential induction of crossreactive immunity to the K562 erythroleukemia cell line, was noted.
Serum GM-CSF pharmacokinetics Serum concentrations of GM-CSF were measured daily for 4 days following the first and third vaccinations in a subset of patients treated at vaccine dose levels 4 (n ¼ 7) and 5 (n ¼ 9) who received vaccines secreting 52 and 104 mg GM-CSF/dose/24 h, respectively. Serum levels of GM-CSF most likely reflect local secretion of GM-CSF from the injected bystander GVAX cells and may therefore serve as a surrogate of in vivo vaccine pharmacokinetics. Alternatively, serum GM-CSF levels might also reflect a host cytokine response to vaccine administration. There was substantial interpatient variability in serum GM-CSF levels, but peak levels generally occurred on day 1 and returned to baseline by day 3 or 4 ( Figure 1a ). Levels 1 day following the first vaccination ranged from 0 to 75 pg/ml (mean 19) and 1 day following the third vaccine from 0 to 160 pg/ml (mean 18). GM-CSF was detected in the serum of most patients for several days after each vaccination, but levels tended to be more persistent after the first vaccination compared to the third, suggesting the possibility of somewhat more rapid clearance of vaccine cells following repeat administration. An allogeneic immune response to the K562 cells could explain this observation. Four patients (25%) had undetectable levels of serum GM-CSF at all time points following the first vaccination, whereas six patients (38%) had undetectable levels following the third vaccination. Patients were analyzed for induction of antibodies against GM-CSF as a potential contributor to clearance of GM-CSF from the serum, and no anti-GM-CSF antibodies were detected. Elevated levels of serum GM-CSF were associated with transient increases in peripheral neutrophil ( Figure  1b ) and eosinophil (Figure 1c ) counts, consistent with biologic activity of secreted GM-CSF. In parallel with the more rapid decay in serum GM-CSF following the third vaccination, neutrophilia and eosinophila were also less pronounced following repeat vaccination.
Immune response
Analysis of immune response to vaccination was hampered by the polyvalent nature of the whole tumor cells used as the immunogen as well as the limited supply of autologous tumor cells available for such analyses. Thus, immune response to vaccination was assessed by measurement of vaccine injection site induration, DTH reactions to intradermal injections of irradiated autologous tumor cells, and induction of tumor-reactive antibodies. An overall summary of immune response data is shown in Table 4 . There was a trend toward a dose-related increase in the frequency of vaccine injection site reactions following the initial vaccination (25, 54, 78, and 79% for dose levels 2, 3, 4, and 5, respectively). In addition, the frequency and size of vaccine injection site reactions increased with repeated vaccinations (61% at vaccine 1 and 74% at vaccine 3). Autologous tumor DTH reactions (X5 mm induration) were detected pre-vaccina- tion in 13% and post-vaccination in 34% across all dose levels; a dose-response trend was not noted.
Antibodies reactive against autologous tumor cells were measured pre-vaccination and 4-12 weeks post-vaccination against autologous lung tumor cells when available.
However, as autologous tumor cells were only available in a subset of patients, analysis was also performed against a panel of allogeneic lung tumor cell lines, the CG9962 K562 bystander GVAX s cells, and control prostate and pancreatic tumor cell lines. Of 35 analyzed patients, 31% developed antibodies reactive against autologous tumor, whereas 86% of 43 patients analyzed showed positive reactivity against at least one of the lung cancer cell lines (with 47-63% of patients responding to each individual lung cancer cell line), and 44% mounted an antibody response to the CG9962 K562 bystander GVAX s cells (Table 4) . A representative example of a serum immunoblot against autologous and allogeneic tumor cell lysates pre-and post-vaccination is shown in Figure 2 . Overall, there was more reactivity against allogeneic tumor cells than against autologous tumor cells, which may simply reflect non-tumor-specific allogeneic responses. In general, antibody induction was measurable within 4 weeks of the first vaccination, was oligoclonal in nature, and patterns of reactivity varied from patient to patient.
Clinical response
No patients achieved a partial or complete tumor response. Seven patients (14%) maintained stable disease for at least 12 weeks following vaccine initiation. Evidence of a mixed response, with regression of at least one tumor mass, was reported in four patients. Median progressionfree survival among the 49 treated patients was 4.4 months and overall survival was 7.0 months. A total of 31% of treated patients were alive at 1 year. Corresponding data for all 86 patients who underwent tumor harvest were as follows: median progression-free survival, 3.7 months; median overall survival, 5.4 months; and oneyear survival, 22%.
Exploratory analyses were performed to determine whether any vaccine manufacturing or immune response parameters demonstrated an association with disease progression or survival. An association was noted for patients with positive vaccine site reactions (45 mm induration). Median progression-free survival for patients with positive reactions was 141 vs 124 days for patients with negative reactions (P ¼ 0.008). This positive association held for overall survival as well. Median survival for patients with positive vaccine site reactions was 278 vs 165 days for patients with negative reactions (P ¼ 0.023). No other significant associations were found between vaccine manufacturing parameters (tumor cell, GM-CSF dose, or viability) or other immune response end points (tumor DTH reactions or antibody induction) and disease progression or survival.
Discussion
This study demonstrates the feasibility of this bystander GVAX s vaccine platform in advanced-stage NSCLC. Manufacturing parameters, in general, compared favorably to previous experience with adenoviral vectormodified autologous NSCLC GVAX s vaccines. 11 Overall, vaccine was successfully manufactured in 88% of harvested patients in this study vs 80% in the previous trial. Additionally, the median tumor cell dose (40 vs 10 Â 10 6 cells/vaccination) and GM-CSF secretion rates (54 vs 2.4 mg/vaccination) were higher with this bystander GVAX s vaccine. Secretion of GM-CSF from the CG 9962 cell line (2600 ng/106 cells/24 h) was also substantially greater in comparison to GM-CSF secretion from transfected autologous human tissue in the prior study. 16 Serum GM-CSF pharmacokinetics were consistent with vaccine-associated secretion of GM-CSF for up to 4 days following repeated vaccinations, and transient postvaccination leukocytosis suggested the biologic activity of secreted GM-CSF, providing biologic proof-of-concept for this bystander GVAX vaccine approach.
Objective evidence of clinical activity was not seen with the bystander GVAX s vaccine tested in this study. This stands in contrast to the objective activity seen in our previous trial of autologous adenoviral vector-based GVAX s vaccines in NSCLC. 11 Despite the higher vaccine tumor cell and GM-CSF doses administered, the rate of positive vaccine injection site reactions was lower in the current study (74 vs 88%). No patients demonstrated objective tumor responses in this trial vs three of 33 complete tumor responses in the previous trial. Similarly, survival among vaccine-treated advanced-stage patients was lower in the current study (median survival 7.0 vs 11.5 months previously). Although historical comparisons may not be valid and are limited by the small sample sizes in both studies, similar eligibility criteria, patient characteristics, vaccine release turnaround times, and rates of patient drop out before vaccine treatment suggest that the patient populations in the two studies are comparable.
Although objective tumor responses were not seen, evidence of vaccine-associated immune activation was demonstrated. This included induction of autologous tumor DTH skin reactions in approximately one-third of patients and induction of antibodies reactive against autologous tumor cells. Antibody induction was not clearly greater against allogeneic lung cancer vs non-lung cancer cell lines, suggesting that most reactivity against allogeneic cell lines is either against shared tumor antigens or is non-tumor-specific. Unfortunately, neither induction of autologous tumor antibody nor DTH reactivity was associated with the clinical end points of progression-free or overall survival. Interpretation of these immune end points might have been confounded by digestion of autologous tumor cells in the presence of fetal bovine serum and collagenase, possibly resulting in non-tumorspecific immune responses. Both reagents have subsequently been successfully removed from the vaccine manufacturing process, making these immune end points potentially more relevant in future trials.
In our previous trial, a threshold effect for vaccine GM-CSF on survival was noted, with longer survival seen in patients receiving vaccines secreting 440 ng GM-CSF/ 10 6 cells/24 h. In the current trial, this threshold effect could not be assessed, as all patients received vaccine GM-CSF doses substantially above this level based on the consistently high GM-CSF secretion (42000 ng/10 6 cells/ 24 h) from the three CG9962 clinical lots used. In the current trial, there was no association between either tumor cell dose or GM-CSF dose and survival. There was, however, an interesting association between induction of vaccine injection site reactions and longer survival. This could reflect either a signal of vaccine activity or simply identify a subset of patients with less cancerassociated immune suppression and inherently better prognosis. 17 These results suggest that fully autologous GVAX s vaccines, generated by transduction of autologous tumor cells with an adenoviral GM-CSF vector, are more potent than bystander GVAX s vaccines in the setting of advanced-stage NSCLC, despite the higher tumor cell dose and GM-CSF secretion delivered with the bystander GVAX s platform. There are several possible explanations for this finding. First, adenoviral GM-CSF vectors may provide an adjuvant effect owing to the presence of residual adenoviral proteins in the vaccine that are not present with the bystander GVAX s approach. This hypothesis is supported by the more frequent induction of vaccine injection site reactions noted in the previous trial and published reports in animals demonstrating potent adjuvant effects of adenoviral GM-CSF vectors formulated with peptide vaccines. 18 Second, an additional advantage of GM-CSF gene-transduced autologous tumor cells over bystander cells may be related to enhanced tumor antigen expression in GM-CSF-transfected cells. 1, 3, 19, 20 Finally, the higher doses of GM-CSF delivered with the bystander GVAX vaccines may have negatively impacted vaccine immunogenicity, owing to induction of myeloid suppressor cells and associated impairment of antigen-specific T-cell responses. Such immunosuppression has been demonstrated in animal studies using high GM-CSF-secreting cellular vaccines. 21 However, the serum GM-CSF levels measured in patients in this study were consistently below the levels associated with immunosuppression in animals (4250 pg/ml) and, generally, were in the range associated with a therapeutic vaccine effect (p40 pg/ml), making this explanation unlikely.
Despite the relative lack of activity of the bystander GVAX vaccine platform in advanced-stage NSCLC, this platform may still be useful in other clinical settings such as hematologic malignancies, where initial clinical data in patients with acute myeloid leukemia and multiple myeloma vaccinated in a state of minimal residual disease are encouraging. 15, 22 Based on these data, however, ongoing clinical trials in NSCLC will focus on adenoviral-transduced autologous GVAX s vaccines. Such vaccines are currently being tested in combination with immunomodulatory doses of cyclophosphamide in advanced-stage NSCLC in an effort to further enhance vaccine potency and as a single agent in advanced-stage bronchioloalveolar carcinoma, a subtype of NSCLC that may be particularly sensitive to this vaccine approach.
